Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer

Inclusion Criteria: 18 years or older; patients with histologically proven diagnosis of ovarian cancer. Patients with metastatic disease and an overexpression of HER2 (as determined by immunochemistry) Patients who have progressed while receiving treatment, or within 6 months after completion of treatment. Patients must have received carboplatin and paclitaxel. Patients who have received at minimum one line of chemotherapy 3 weeks minimum since last treatment with chemotherapy must have elapsed Patients must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) or an assessable cancer antigen (CA) 125 > 1.25 x upper limit of normal (ULN) Patients must have ECOG of 2 or less Left ventricular ejection fraction (LVEF) of 50% or better Patients have given their signed and verbal consent Exclusion Criteria: Previous treatment with Herceptin or similar products affected growth factors (eg: Iressa) Another experimental treatment in the previous 30 days No overexpression of HER2 receptors Patients having received high-dose chemotherapy or stem-cell interventions Other cancers within the last 5 years Patients with dyspnea at rest or requiring oxygen therapy